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Abstract
Utilization of a cerebral protection device during transcatheter aortic valve replacement (TAVR)
will reduce the rate of periprocedural stroke as well as the occurrence and volume of new lesions
on diffusion weighted magnetic resonance imaging (DW-MRI), which may serve as a potential
surrogate endpoint for clinical studies. The DEFLECT I study is a prospective, multi-center,
single arm study that aims to demonstrate the safety and performance of the TriGardTM Embolic
Deflection Device (EDD) (Keystone Heart, Caesarea Business Park, Israel), among patients
undergoing TAVR. Primary endpoints were device performance and in-hospital device-related
safety. A powered secondary endpoint was the number and volume of new DW-MRI brain
lesions. Of the 20 consecutive patients enrolled, the device performed as intended with complete
vessel coverage until completion of the valve implant in 80% of cases. The hierarchical
composite in-hospital procedure-related major adverse cardiac and cerebrovascular (MACCE)
event rates was 10% due to 2/20 major disabling strokes, which occurred the day after the
procedure following urgent surgery for a failed TAVR implant and a cardiac arrest due to loss of
pacer capture. Compared with historical controls, the number of new ischemic brain lesions
detected on DW-MRI were similar (70% vs. 76%); however, patients undergoing TAVR with
the TriGardTM EDD device demonstrated a 94% reduction in the maximum lesion volume, a
94% reduction in maximum total lesion volume, and a 65% reduction in mean lesion volume
compared with historical controls. An angiographic sub-study demonstrated that the only clinical
factor associated with the maintenance of device coverage throughout the procedure was
anchorage of the upper stabilizer in the innominate artery. The DEFLECT I study established
proof of concept of the TriGardTM device and justifies further evaluation in a planned
randomized clinical trial.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR) is increasingly used to treat patients with aortic
stenosis deemed high or extreme surgical risk candidates. Since its introduction in 2002, clinical
trials have proven its feasibility, safety, and efficacy. Further, the randomized, controlled
PARTNER trial demonstrated the superiority of TAVR to standard balloon valvuloplasty in
patients at extreme risk and its non-inferiority compared with surgical aortic valve replacement
(SAVR) in high surgical risk patients[1]. However, TAVR is not without its complications.

Stroke has emerged as a major source of morbidity and mortality in patients undergoing the
procedure[2, 3]. The periprocedural incidence of stroke has been estimated at 1.5% +/- 1.4%[2],
but rates as high as 10% have been reported[4]. Stroke is also a known contributor to acute and
ongoing mortality rates[5, 6].

In the following, we will define “stroke” and transient ischemic attack (TIA) according to the
2012 VARC-2 definitions[7]. The pathogenesis of stroke or TIA associated with TAVR likely
involves cerebral embolization during device positioning and implantation[5]. The nature of the
TAVR procedure lends itself to catheter manipulation of the calcified aortic valve and
atherosclerotic aorta. Likewise, most studies show a consistent link between both TAVR and
SAVR and embolic lesions visualized on diffusion-weighted-magnetic resonance imaging (DWMRI). Similar clinically silent lesions only identified with neuroimaging have been designated as
“silent” strokes[8]. The question of whether these TAVR-related lesions lead to an increased risk
of future cerebrovascular events with even longer term cognitive consequences remains open,
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but given the large literature on silent strokes and cognition, this association is probable, with
significant clinical implications.

We will explore the likely significance of asymptomatic lesions seen on DW-MRI and present
data supporting the link between silent stroke and cognitive decline in order to demonstrate the
need for cerebral embolic protection during TAVR. Finally, we will discuss potential therapeutic
options, including cerebral protection devices currently under investigation, to prevent stroke
related to TAVR.

Clinical Significance of DW-MRI Lesions
DW-MRI detects changes in the self-diffusion of water molecules associated with ischemic
injury[9]. In conjunction with the apparent diffusion coefficient, it is able to distinguish between
cytotoxic edema caused by tissue infarction and vasogenic edema. DW-MRI is highly sensitive
for detecting brain ischemia, and widely available, making it a suitable method for detecting
neurovascular events acutely following interventional procedures[10].

Early prospective studies investigating the risk of cerebral embolization associated with
endovascular cardiac procedures, involving crossing of a stenotic aortic valve, demonstrated new
post-procedure DW-MRI lesions in 2-22% of patients[11, 12]. A higher rate is expected with the
bulkier devices utilized in balloon valvuloplasty and TAVR, and new foci of restricted diffusion
on DW-MRI, consistent with embolic lesions (Fig. 1), have been demonstrated to occur in 6884% of TAVR patients, with more than 75% of patients enduring multiple new foci[9, 13, 14].
The majority are asymptomatic with neurologic symptoms occurring in less than 10% of
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patients[14, 15]. Though few studies have investigated their clinical significance in the context
of TAVR, there are multiple studies showing the association of new DW-MRI lesions with
cognitive
impairment
following other
cardiac procedures
(Table 1).

First, Restrepo et al.
demonstrated that in
patients undergoing
Figure 1. Diffusion weighted-magnetic resonance images: (A) Baseline. (B)
Following embolic event. Arrows indicate areas of restricted diffusion.

coronary artery
bypass grafting,

those with new DW-MRI lesions following the surgery had significantly greater declines in
cognitive function than those with stable MRI, evident as absolute changes in
neuropsychological test performance. In fact, the number of new DW-MRI lesions was
correlated with the degree of overall decline as measured within 1 week following surgery[16].
Barber et al. investigated the relationship between post-operative DW-MRI lesions and cognitive
decline at 6 weeks, defined as a drop in the Reliable Change Index in at least 1 cognitive
measure, following valvular surgery. They found that all patients with postoperative DW-MRI
lesions had cognitive decline on at least 1 neuropsychological measure compared with only 35%
of those without ischemic change[17].
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In patients undergoing left heart cardiac catheterization, more than 16% of patients had postoperative cognitive decline (POCD) following the procedure, defined as a drop of at least 20%
on at least 2 of the 12 selected test variables, and patients with DW-MRI lesions failed to show
improvement on repeat neuropsychological testing, as compared to those without such
lesions[18]. The degree of cognitive decline was related to whether new lesions appeared on
DW-MRI post-procedure. In addition, Schwarz et al. compared neuropsychological outcomes in
patients undergoing coronary catheterization and coronary artery bypass grafting up to 3 months
following the procedure. Indeed, the presence of DW-MRI lesions correlated with POCD in 3
cognitive domains when performed at 3 months as compared to baseline[19].

On the other hand, some studies suggest that DW-MRI lesions may be clinically irrelevant due to
apparent reversability[13]. Importantly, DW-MRI lesion reversal may not indicate normalization.
Animal studies have shown that even with DW-MRI hyperintensity reversal after ischemia,
neurons exhibit structural damage and stress, and histological staining suggests that other nonneuronal cell populations may compensate for the altered fluid balance seen on follow up
imaging[20]. Alternatively, the lesions may simply drop below the sensitivity of standard DWMRI, as high field strength (3 Tesla) imaging has revealed significantly more lesions than 1.5
Tesla studies[21].

There is no data on the long-term consequences of DW-MRI lesions associated with TAVR,
however extrapolation from the short-term studies noted above indicates that they cannot be
dismissed. A number of studies have concluded that DW-MRI lesions are not predictive of longterm POCD after cardiac surgery[22-24], but the limitations of these individual studies suggest
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discrepancies in research methodology that should be improved (Table 1). The studies noted
utilized 1.5 Tesla imaging, which may have failed to detect showers of small emboli and thus
missed a potential association. In addition, the appropriate DW-MRI endpoint for cardiac
procedures has not been defined and these studies reported various lesion characteristics,
including mean lesion volume, maximum lesion volume, and number of lesions per patient,
therefore increasing the difficulty of cross-study comparison.

Importantly, the neuropsychological testing performed in these studies utilized batteries of
multiple individual tests (Table 2). The problem with using multiple individual tests selected at
the investigator’s discretion is the variability of cognitive domains covered. TAVR-related DWMRI changes likely impact cognition in subtle ways and this association may be obscured if the
cognitive domains most susceptible are not evaluated adequately and/or if neuropsychological
instruments that are not sensitive to subtle injury are employed. Further, there is no standard
definition for POCD associated with cardiac procedures, suggesting that determination of
cognitive decline may vary between studies. There is also no standard neuropsychological
battery for cardiac surgery and catheterization, including TAVR. The neuropsychological tests
used have been proposed for the detection of vascular dementia, but the selection of tests that
may be specific for this diagnosis might not be sensitive to cognitive change following the
TAVR intervention[25].

Thus, large, prospective studies with adequate follow-up would help to clarify the association of
DW-MRI lesions with clinical outcome following cardiac catheterization procedures, especially
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TAVR. A standard neuropsychological battery for measuring cognition after cardiac procedures
is also necessary.

Silent Stroke and Cognitive Decline
The relationship between stroke and cognition is well established[26, 27]. Silent stroke is also
related to neurodegenerative and psychiatric diseases as well as decline in cognitive and motor
abilities in the absence of frank dementia. The prevalence of silent strokes in the elderly
population ranges between 13-21%[28, 29] and increases to 30-40% in patients older than 70
years[30]. Although the association of DW-MRI lesions after TAVR with cognitive decline is
under debate, there is a growing body of evidence linking silent strokes to poor cognitive
outcomes and neurodegenerative diseases.

A “silent” stroke is an area of infarction seen on neuroimaging in the absence of neurological
signs or symptoms. Blood flow in silent stroke is compromised and therefore results in neuronal
damage, just as in symptomatic infarction. Patients with silent stroke demonstrate “misery
perfusion,” where there is a decrease in cortical blood flow with an increase in oxygen extraction
fraction. They also exhibit diaschisis in which subcortical silent stroke actually causes blood
flow to decrease in the superior cortical areas[8].

Evidence for association between silent infarcts and cognitive dysfunction:
The correlation between asymptomatic infarcts and cognitive impairment is convincing. In a
prospective study of 1015 elderly people, Vermeer et al. demonstrated that over a 5 year period,
the presence of silent brain infarcts at baseline more than doubled the risk of dementia, with
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Alzheimer’s Disease being the most common type (HR 2.26, 95% CI [1.09-4.70])[28]. The rate
of new silent brain infarcts was higher in patients who developed dementia than in those who did
not. Further, the presence of silent strokes was associated with significantly worse global
cognitive function as well as a steeper rate of cognitive decline. Notably, the presence of
multiple silent infarcts was more strongly correlated with cognitive decline than single
infarcts[28]. Likewise, Blum et al. studied 658 community-dwelling elderly individuals who
received MRI and found that those with any brain infarct had smaller hippocampi than those
without. They also found that brain infarcts and smaller hippocampus volumes were
independently associated with poorer memory, suggesting that a history of brain infarcts can
contribute to a functional state similar to that of early Alzheimer’s Disease[31].

It is also known that symptomatic strokes contribute to poorer executive function in patients with
Alzheimer’s Disease[32]. Similarly, Song et al. found that silent stroke was associated with
increased severity of cognitive decline in patients with Alzheimer’s Disease[33]. An association
between silent stroke and cognitive impairment, self-perceived health status, and independence
in community dwelling elderly people has also been shown[29].

In addition to cognition, silent strokes are also associated with depression and motor functional
deficits. Fujikawa et al. observed the presence of silent stroke in 51.4% of patients with
depression and in 93.7% of those with senile-onset depression[34]. Lastly, in a recent rat model,
Faraji et al. demonstrated that repetitive focal ischemic mini-lesions to the sensorimotor cortex
resulted in a decreased ability to accurately perform a walking task, indicating that concurrent
silent strokes to the cortex can impair motor function[35].
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Thus, the accumulation of silent strokes over time likely contributes to cognitive impairment and
neurodegeneration. Even 1 silent stroke puts people at risk for cognitive decline and
dementia[28]. We suspect that such lesions lower the thresholds for future clinically significant
strokes as well as the clinical expression of other neurodegenerative pathologies like Alzheimer’s
Disease. In addition, silent strokes are associated with steeper cognitive decline in patients with
diagnosed dementia. Because TAVR-related microemboli often cause multiple new silent
strokes that may contribute to the ischemic burden of the patient, the need for cerebral embolic
protection is great.

Embolic Protection in TAVR
Cerebral embolic protection may be accomplished through drugs, such as anti-platelet or
antithrombotic regimens, and devices, including capture or deflective devices.

Anti-thrombotic regimens:
The literature is scarce regarding the appropriate anti-thrombotic regimen for TAVR. The only
randomized trial to date evaluated the need for dual anti-platelet therapy with aspirin and
clopidogrel for 3-6 months after the procedure in 79 patients and found no clinical benefit from
the addition of clopidogrel[36]. This finding is important because patients with chronic atrial
fibrillation treated with warfarin and aspirin demonstrate a significantly increased bleeding risk
with the addition of clopidogrel for catheterization procedures[37]. Larger, prospective studies
would be helpful in assessing the need for and type of antithrombotic therapy for patients
undergoing TAVR.
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Cerebral protection devices:
Given the temporal pattern and arterial distribution of the majority of TAVR-related infarcts[5],
peri-procedural cerebral embolization is the most likely mechanism of cerebral infarction.
Therefore, anti-thrombotic regimens are unlikely to provide as much benefit as filter-based
protection devices, the utility of which has been demonstrated in carotid artery stenting. There
are a few devices that have been developed specifically for cerebral protection in TAVR. These
include the Claret CE ProTM, the Embrella (Edwards Lifesciences, Irvine, CA, USA) deflection
system, and the TriGardTM embolic DEFLECTion device (EDD) (Keystone Heart Ltd., Herzliya,
Israel), which vary in their delivery sheath sizes, routes of delivery, and vessel coverage (Table
3).

The Claret CE ProTM (Fig. 2) is the only device that captures and removes debris from the body.
The device uses a 6F transradial or brachial delivery system, a 9-15 mm brachiocephalic artery
filter, and a 7-10 mm left common carotid artery filter, with 140-micron pore sizes[38]. The firstin-man trial in 35 patients
demonstrated first-generation
device and second-generation
device success rates of 60%
and 87%, respectively. Debris
was captured in 54.3% of
patients and no procedural
cerebrovascular events
Figure 2. The Claret CE ProTM.
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occurred; however 1 patient experienced a minor stroke and 2 patients suffered major strokes
within 30 days of the procedure; 1 major stroke occurred within 4 hours of the procedure[38].
This study was limited by the absence of pre- and post-procedural neuroimaging as well as tests
of neurocognitive function.

Like the Claret CE ProTM, the
Embrella (Fig. 3) only covers
the innominate and left carotid
arteries, but may also cover the
left subclavian artery up to 60%
of the time. The device also
uses a 6F transradial or brachial
delivery system. It consists of
100 micrometer sized pores on
Figure 3. Embrella embolic deflector.

a membrane mounted on a
Nitinol frame and shaft, with 3 radiopaque markers to aid fluoroscopy-guided delivery. The
first-in-human study successfully employed the device in 4 patients without damage to the
arteries or interference with the TAVR procedure. None of the TAVR patients exhibited new
periprocedural neurologic symptoms or new findings on pre-discharge MRI, however one patient
who underwent balloon valvuloplasty alone demonstrated a new 5-mm acute cortical infarct in
the right temporal lobe[39].
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The TriGardTM EDD (Fig. 4) covers all 3 cerebral inflow vessels and is delivered via the
transfemoral route. It uses a larger delivery catheter (9F) via the contralateral transfemoral
approach, and a heparincoated Nitinol mesh to
deflect embolic debris. A
vertical stabilizer is
positioned in the innominate
artery and lower feelers
anchor the device against the
upper wall of the aortic arch.
It is the only system that
Figure 4. Keystone Heart TriguardTM Embolic Deflection Device.

covers all 3 of the great

vessels branching off of the aorta, providing the maximal scope of protection[40]. A pilot study
of 15 patients demonstrated device safety, and significant reduction in embolic events (average
of 3.2 new DW-MRI lesions per patient vs. 7.2 per historical)[40]. The only neurological
complication involved 1 patient suffering a TIA within 2 days of the procedure. A 60 patient CE
mark trial is currently underway with formal DW-MRI and neuropsychological assessment.

Embolic protection devices show promise in decreasing the rate of cerebral embolization and
stroke in patients undergoing TAVR but their ability to prevent or decrease the long-term
occurrence of stroke is unclear. Likewise, cerebral infarction due to procedural hypotension as
well as continued embolization from the calcific, degenerated native valve cusps and valve
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prosthesis would not be affected by the use of procedural deflection devices. These issues remain
to be addressed with further refinement of TAVR.

Neuro-Imaging as an Endpoint Measure
Choosing an appropriate endpoint for a clinical trial can be complex. In fact, up to 10-15% of
medical devices that enter the EU regulatory pathway lack relevant endpoints, which is
considered grounds for objection. The penetration rate of devices in general, and in TAVR
specifically, is significantly delayed in the US compared to Europe mostly due to FDA
requirements for reasonable assurance of safety and effectiveness of a device prior to its approval
[40].

For clinical trials investigating neuro-protection devices for use in cardiac procedures, the
investigators must prove that the device is able to reduce the occurrence and/or severity of
cerebral events. Ideally this would be accomplished by reporting an actual reduction in the rate
of stroke, transient ischemic attack, and other neurologic events according to Valve Academic
Research Consortium-2 definitions [7]. Because the occurrence of TAVR-related stroke is
relatively low (<10%), a large sample size would be needed to detect a difference in clinical
event rate with versus without a protection device. In addition to sample size requirements, the
rising cost of clinical trials limits the feasibility of using relatively uncommon clinical events as
trial efficacy endpoints. Further, silent ischemia accounts for the majority of lesions detected on
neuro-imaging following TAVR procedures. Using a clinical event endpoint to measure device
success would miss the occurrence of these silent lesions, which are associated with cognitive
decline and mortality [41, 42].
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Neuro-imaging, specifically DW-MRI, may serve as a surrogate endpoint for clinical studies
detecting cerebral events in which cost and sample size limitations prohibit the use of clinical
outcomes. DW-MRI, which has sensitivity and specificity up to 92% and 97%, respectively,
combines features of conventional spin echo and gradient echo techniques to image the freedom
of the diffusion of water molecules to identify restriction in diffusion, suggestive of cerebral
ischemia [43]. In cytotoxic edema due to hypoxia, the re-distribution of water from the
extracellular to the intracellular space is visible within zero to five days of the event (Fig. 1). On
DW-MRI, normal tissue appears gray due to the Brownian motion and diffusion of water
molecules, whereas restricted diffusion in the case of ischemia prevents the normal loss of MRI
signal and thus appears white. A bright signal on DW-MRI and a dark signal on the
corresponding apparent diffusion coefficient map is characteristic of acute brain injury within
five days.

One important issue to consider is that evidence for long-term consequences of lesions detected
by DW-MRI is lacking. Indeed, recent studies have implied that DW-MRI lesions after TAVR
are not related to self-sufficiency or mortality one-year post-procedure and that there may even
be less cognitive decline post-TAVR compared with surgery, despite a higher incidence of
embolic lesions [44, 45]. These studies are limited by small sample sizes but they suggest that
there may limitations in utilizing DW-MRI to evaluate TAVR outcomes.

Another major limitation of using DW-MRI in clinical trials is that no clear definition of the
endpoint exists. Qualitative measurements include lesion number and vascular territory involved
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and quantitative measurements include total lesion volume, average lesion volume, and
maximum lesion volume. All are key neuro-imaging endpoint parameters to follow the efficacy
of neuro-protection, however, the endpoint must be standardized to allow for cross-study
comparison.

Ongoing clinical trials investigating cerebral protection devices for TAVR are utilizing various
DW-MRI measures to determine device efficacy. The ongoing Prospective Randomized
Outcome Study in Patients Undergoing TAVR to Examine Cerebral Ischemia and Bleeding
Complications (PROTAVI) trial, which is randomizing patients eligible for TAVR to undergo
the procedure with or without the Embrella deflection device, will analyze the rate of new DWMRI brain lesions at seven days post-procedure. Likewise, the DEFLECT I trial is a single arm
study enrolling up to 60 patients in the EU, Canada, and Brazil to undergo TAVR with the
Keystone Heart TrigardTM in place using the presence of new DW-MRI lesions post-procedure
compared with a historical control group as a measure of device success.

Although DW-MRI lesion presence and rate of occurrence are being used as endpoints, total
lesion volume is the most reproducible measurement when performed in an experienced core
laboratory, and along with geographic location, provides the best measure of overall burden of
ischemic injury, and may therefore be a more appropriate endpoint measure. Though it fails to
identify the functional region of the brain involved, studies have identified DW-MRI lesion
volume as an independent predictor of clinical outcome after acute stroke [46, 47]. Specifically,
mean lesion volume has been correlated with mental changes and vascular dementia following
endovascular procedures [48]. In contrast, the presence and number of DW-MRI lesions are only
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likely to be clinically relevant if the individual lesion is large or in an area of functional
significance [49]. Therefore, the Yale-University College of London (UCL) summit concluded
that DW-MRI lesion volume should be measured by independent core laboratory assessment
with validated and reproducible methodology and should be included and reported in all clinical
studies using DW-MRI to investigate neuro-protection devices for use in TAVR. We recommend
that single lesion volume, number of new ischemic lesions, and total lesion volume be measured.

Lastly, in 2011, the FDA issued draft guidance for clinical trial imaging endpoints for studies
intending to confirm drug efficacy, recognizing that the use of imaging may assist in the
assessment of safety and efficacy as well as patient eligibility. US regulatory requirements have
been an impediment to early clinical testing of new devices, which US investigators have mostly
out-sourced overseas. During the Yale-UCL summit, the FDA expressed its goals to encourage
medical device innovation, enhance regulatory science, and facilitate early feasibility clinical
studies in the US. Consensus from the 2013 Yale-UCL summit called for validation of imaging
endpoints in neuro-protection trials involving medical devices and encouraged European
regulatory bodies and the FDA to work with the clinical and device industry to support this
position [50].

In summation, filter-based embolic protection devices, the utility of which has been
demonstrated in carotid artery stenting, show promise as a means of preventing stroke and other
neurologic complications following TAVR. Prevention of neurological complications is
necessary in order to fully realize the potential of TAVR and optimize the outcomes of patients
with severe aortic stenosis. Mean and total lesion volume, as measured on DW-MRI, may be
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appropriate surrogate endpoints for clinical studies like DEFLECT I. We report the results of the
DEFLECT 1 clinical trial, which was designed to demonstrate the safety and performance of the
TriGardTM EDD.

17 17

HYPOTHESIS
Patients undergoing TAVR with the Keystone Heart TriGardTM EDD in place will demonstrate a
lower rate of periprocedural stroke, as well as a reduction in the number and volume of new
brain lesions on DW-MRI.

SPECIFIC AIMS
1. To evaluate the safety and performance of the Keystone Heart TriGardTM EDD in patients
undergoing TAVR
2. To determine the risk of clinical stroke with the EDD in place.
3. To evaluate the occurrence and size of new DW-MRI brain lesions with the EDD in place
as compared with historical controls.
4. To evaluate the impact of baseline cardiac anatomy and procedural characteristics on
device position and function throughout the TAVR procedure.
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METHODS
Study Design and patient population
The DEFLECT 1 clinical trial is a prospective, multi-center, single arm study, designed to
evaluate the safety and performance of the TriGardTM EDD in patients undergoing TAVR for the
purpose of obtaining European Union (CE Mark) approval on the basis of 20 consecutive
patients, but allowing extended enrollment of up to 60 patients from up to 10 investigational sites
in the European Union, Brazil and Canada.

Patients were included if they were older than 18 years of age, met current indications for
TAVR, and were willing to comply with protocol-specified follow-up evaluations. Patients were
excluded from the study if they were undergoing TAVR via the trans-axillary, subclavian, or
direct aortic route, were in cardiogenic shock, or had a known myocardial infarction (MI) within
72 hours of the procedure, had impaired renal function (Glomerular Filtration Rate <30);
bleeding diathesis, coagulopathy, or refusal of blood transfusion, past or pending organ
transplantation, known medical illness or history of substance abuse that could interfere with
compliance, stroke, TIA, known hypersensitivity or contraindication to aspirin, heparin/
bivalirudin, clopidogrel/ticlopidine, nitinol, stainless steel alloy, and/or contrast sensitivity that
could not be adequately pre-medicated, severe peripheral arterial disease precluding delivery
sheath vascular access, documented friable or mobile atherosclerotic plaque in the aortic arch,
contraindication to cerebral DW-MRI, or had planned treatment with any other investigational
device or procedure during the study period. Patients meeting eligibility criteria for TAVR were

19 19
enrolled in the study after providing written informed consent. A medical ethics committee/
Institutional Review Board approved the study.

Device description
The TriGardTM EDD (Fig. 4) is intended to be delivered percutaneously via a 9 Fr sheath and
positioned in the aortic arch to deflect and reduce embolic material (debris/ thrombus) to the
cerebral arteries during endovascular procedures. It is a temporary single use, biocompatible
filter, made of fine nitinol #1 (nickel titanium alloy) wires, which is anchored in position by an
atraumatic stabilizer, positioned in the ostium of the innominate artery (Fig. 5). The filter portion

Figure 5. Angiography demonstrating Keystone Heart Triguard TM device position. (A) Before the TAVR
procedure. White arrow indicates device upper stabilizer anchorage in innominate artery. (B) During the
TAVR procedure. (C) After the TAVR procedure. TAVR, transcatheter aortic valve replacement.

of the device covers all three major cerebral arteries in the aortic arch (innominate, left common
carotid and subclavian) and maintains blood flow to the cerebral vessels through 250 m sized
pores, while deflecting larger embolic/particulate matter toward the descending aorta. The filter
is coated with an antithrombotic coating (Applause™ Heparin Coating, Surmodics, USA).
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Screening and Procedure Description
A series of routine tests were performed to assess general patient eligibility for the study
including cardiac biomarkers (CK, CK-MB isoenzyme and troponins) within 24 hours of the
procedure to exclude MI and a baseline computed tomography angiogram (CTA) of the left
heart, aortic arch and great vessels extending to the peripheral access vessels per standard of
care. Patients meeting eligibility criteria signed informed consent prior to enrollment in the
study. DW-MRI of the brain was performed within 21 days prior to the procedure.
Comprehensive neurological assessments were performed at baseline, including the NIH Stroke
Scale, the Modified Rankin Scale and the Montreal Cognitive Assessment (MoCA).[51] These
were performed within one week of the procedure by a trained and qualified individual, and
repeated by a neurologist or neurology fellow when a stroke or TIA was suspected.
All patients were treated with a 300-325 mg loading dose of aspirin and 75-325 mg of aspirin
prior to the procedure, and either 300 mg of clopidogrel 6 hours before the procedure or 600 mg
peri-procedurally. Following the procedure, the recommended antiplatelet regimen was ASA 75
mg daily indefinitely and 75 mg daily of clopidogrel for at least 6 months.

TAVR was performed according to standard institutional practice under local or general
anesthesia using a transapical or transfemoral approach as indicated.

At the start of the

procedure, a 9Fr arterial sheath was inserted in the contralateral femoral artery, the EDD device
was advanced and deployed across the aortic arch, covering the ostia of the 3 major neck vessels
(innominate, left common carotid and subclavian) and withdrawn at the completion of the TAVR
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procedure. The procedure was complete once the guiding catheter was removed from the patient
and the patient was off the table.

Clinical Follow-up
Follow-up DW-MRI of the brain was performed at 42 days (range 2-6 days) post-procedure. A
one-month clinical follow-up visit was scheduled for 307 days post-procedure for anginal status
(Canadian Cardiovascular Society, Braunwald or silent ischemia) and any adverse events. A
neurologic evaluation consisting of the NIH Stroke Scale, Modified Rankin Scale, and MoCA,
was performed at discharge and 1 month follow-up by an independent qualified individual and
repeated by a neurologist or neurology fellow if a stroke or TIA was suspected.

Endpoints and Definitions
Primary Endpoints
The study had two primary endpoints: The primary device performance endpoint was defined as
the ability to (1) access the aortic arch with the delivery catheter, (2) deploy the EDD, (3)
position the device to cover all 3 cerebral inflow vessels (verified by angiography) without
obstruction of blood flow or interference during the TAVR procedure, and (4) retrieve the EDD
device and delivery system, in the absence of adjudicated device malfunction (Fig. 5). Device
malfunction was defined as the failure of the EDD to perform in accordance with its intended
use.
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The primary safety endpoint was in-hospital device and procedure-related safety, defined as the
incidence of investigational device and investigational procedure-related serious adverse events
in a composite hierarchical safety endpoint. The components of this safety endpoint included:
Valve Academic Research Consortium (VARC) defined as (1) cardiovascular mortality, (2)
major stroke disability, (3) life-threatening or disabling bleeding[52], (4) distal embolization
(noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible
end organ damage, major vascular or access-related complications and (5) need for acute
cardiovascular surgery (defined as immediate transfer from the catheterization lab to the
operative room during the initial treatment phase due to the need for emergency coronary artery
bypass graft surgery, cardiac valve surgery, or other vascular surgical intervention).
Secondary Endpoints
A major powered secondary efficacy endpoint was the number and volume of new embolic
lesions detected by DW-MRI of the brain from pre-procedure to 4±2 days (range 2-6 days) postprocedure compared to a historical control (Table 3).
Additional secondary performance endpoints included: (1) procedure success, defined as
successful device performance without the occurrence of the primary composite safety endpoint
(defined above); (2) device deployment time (defined as the time elapsed between insertion of
the EDD into the delivery sheath and successful deployment into the aortic arch); and (3) total
procedural time (defined as the time elapsed between the first arterial access and removal of the
last guiding catheter from the arterial access sheath).

Other secondary safety endpoints were measured in hospital and at 30 days and included: (1)
device-related safety (component and hierarchical composite), as defined above for the primary
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safety endpoint, (2) Major Adverse Cardiac and Cerebrovascular Events (MACCE) defined by a
hierarchical composite endpoint of VARC-defined all-cause mortality, major stroke disability,
life-threatening (or disabling) bleeding, acute kidney injury – stage 3, peri-procedural MI, major
vascular complication, and repeat procedure for valve-related dysfunction[52]; (3) VARCdefined all cause and cardiovascular mortality, periprocedural and spontaneous MI, major and
minor vascular complications, acute kidney injury, and neurological events (both component and
composite), including stroke and its sub-classifications[52], as well as cerebral infarction
(defined as evidence of brain cell death from imaging studies or pathological examination),
encephalopathy (defined as altered mental state, e.g., seizures, delirium, confusion,
hallucinations), and intracranial hemorrhage (defined as a collection of blood between the brain
and skull, subcategorized as epidural, subdural, and subarachnoid bleeds), and cognitive
dysfunction as assessed by the MoCA.

Study Conduct and Central Laboratories
Site monitoring was performed for 100% of clinical fields and clinical events (MedPass
International, Paris, France). All adverse events were adjudicated by an independent Clinical
Events Committee (Yale Cardiovascular Research Group, New Haven, CT) and all neurologic
evaluations including NIH Stroke Scale, Modified Rankin Scale and MoCA were independently
reviewed by an expert neurologist (AB, Columbia University, New York, NY). Three
independent core laboratories were used for independent assessment of imaging data and
endpoint measures.
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Angiographic Core Laboratory (Yale Cardiovascular Research Group, Yale University, New
Haven, CT): All procedural angiograms were sent and reviewed independently by qualified
analysts trained in the procedure, the investigational device and its intended use. The
angiographic analysis included the first consecutive 20 patients enrolled in the trial. An
independent angiographic core laboratory performed comprehensive quantitative coronary
angiography of baseline and final angiograms using validated methods (Medis, Leiden, The
Netherlands). All EDD performance criteria including successful 1) access of the aortic arch with
the delivery catheter, (2) deployment of the EDD, (3) positioning of the device to cover all 3
cerebral inflow vessels without obstruction of blood flow or interference with the TAVR
procedure, and (4) removal of the device, were adjudicated by the core laboratory and used for
reporting of the primary endpoint. Further angiographic analysis consisted of determining,
before, during, and after the TAVR procedure, whether the EDD covered all 3 aortic arch
vessels, whether the EDD upper stabilizer was anchored in the innominate artery ostium, and the
aortic arch classification. In addition, the innominate artery reference vessel diameter (RVD),
take off angle from the innominate artery and aortic arch, take off angle from the EDD after
positioning in the aortic arch, and take off angle from the EDD after TAVR were measured. All
cases were reviewed for quality control by the laboratory director.

Diffusion-Weighted MRI Core Laboratory (Global Research Institute, Richmond, VA): All
baseline and follow-up DW-MRI images were reviewed and analyzed by an independent core
laboratory. The analysis was performed blinded to temporal sequence, using validated
qualitative and quantitative methods (Vitrea, Version 6.3.2; Olea, NeuroScape; Version 1.2.0).
Axial DW-MRI images and corresponding apparent diffusion coefficient (ADC) maps, as well as
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corresponding T2-weighted images were reviewed for the presence of lesions with high signal
intensity on DW-MRI. Acute ischemic lesions were defined as those areas of high signal
intensity on DW-MRI with corresponding areas of low signal intensity on the ADC maps.
Corresponding T2-weighted images were also reviewed for T2-shine through. Coronal and
sagittal image reformats were also reviewed to determine whether lesions were single or
multiple. For each patient, the total number of lesions on the pre-TAVR DW-MRI, the total
number of lesions on post-TAVR DW-MRI, and the total number of new lesions were recorded.
For each positive lesion on DW-MRI, the number of positive voxels, as measured with the Olea
software, and the volume of each lesion were recorded. Lesion volumes were summed across
each patient to yield total lesion volume.

CT Angiography Core Laboratory (Global Research Institute, Richmond, VA): All preprocedural CTAs were forwarded to an independent CT angiographic core laboratory to perform
independent assessment of anatomic measures potentially related to device performance and
cerebral embolization including vessel tortuosity, presence and extent of valve and vascular
calcification and plaque among others. All quantitative measures were performed using
validated software (Medis, Leiden, The Netherlands).

Statistical Analysis
The intent to treat population is the primary analysis population for DEFLECT I. Continuous
variables are presented as mean  standard deviation (SD). Binary variables are described as
frequencies and percentages. The hypothesis of the powered secondary efficacy endpoint is that
the EDD will be superior to the historic control with respect to the number and volume of new
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embolic lesions detected by DW-MRI of the brain from pre- to post-procedure. The historic
control for new cerebral lesions was derived from a weighted average of 5 clinical trials (Table
1)[9, 13, 15, 53, 54]. These trials were chosen due to similar inclusion/exclusion criteria and
similar time points for DW-MRI follow-up. Thus, the control event rate based on contemporary
data is assumed to be 76%. The sample size is calculated for the hypothesis of superiority
assuming 90% power to detect a 40% reduction in DW-MRI lesions with the EDD. With a twosided α=0.05, a minimum total of 28 patients treated with the EDD would provide 90% power to
conclude that the EDD was superior to historical controls without neuro-protection. The protocol
allows continued enrollment of up to 60 patients to account for loss to follow-up or
contraindication to a post-procedure DW-MRI (e.g., pacemaker implantation) to meet the
efficacy endpoint. For the angiographic sub-study, all statistical analyses were performed using
SAS version 8.2 (SAS Institute Inc, Cary, North Carolina). Categorical variables are presented as
frequencies and were compared with Pearson chi-square or Fischer’s exact test. Continuous
variables are presented as mean  SD and were compared with ANOVA or the Kruskal Wallis
test.

Contributions
I participated in protocol development and revision, as well as weekly teleconferences with the
trial sponsor and monitor. Patient enrollment and data collection were performed by individual
investigators at the international sites. I led the clinical events committee, which served to
adjudicate all adverse events. My responsibilities for that role included obtaining source
documents from the international sites, writing detailed narratives for each adverse event and
angiographic analysis, preparing adverse event and adjudication forms, as well as recruiting a
diverse panel of 4 clinical experts from Yale to adjudicate each event. I also assisted with
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presentation preparation for the sponsor meetings, performed interim and periodic statistical
analyses, drafted the manuscript for publication and am currently participating in revisions. For
the angiographic sub-study, I designed the study, collected all of the data, performed the
statistical analyses in SAS, wrote the abstract, and gave the oral presentation at EuroPCR.
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RESULTS
A total of 20 patients were enrolled in DEFLECT I from 5 actively participating clinical EU
sites, including 8 patients from University College of London Hospitals, 2 patients from
University Hospitals of Leicester, 2 patients from Brighton and Sussex University Hospital, 7
patients from University Hospitals of Bristol, and 1 patient from Amphia Ziekenhuls
Molengracht Breda. The study population is representative of subjects undergoing TAVR with
high or extreme risk indications (Table 4). A total of 21 valves were implanted in 20 patients
through the transfemoral approach with general anesthesia in 90.0% (18/20); 47.6% (10/21)
recieved the Edwards SAPIEN heart-valve system (Edwards Lifesciences, USA) and 52.4%
(11/21) the Medtronic CoreValve® system (Medtronic, Inc., USA). Pre-TAVR balloon
valvuloplasty was performed in 16/20 (80%) cases. TAVR implantation was successful in 19
out of 20 cases. A single case required urgent conversion to surgical aortic valve replacement
after failed implantation of 2 TAVR devices complicated by severe aortic insufficiency.

Primary endpoints
A total of 21 EDD devices were successfully delivered to the aortic arch in 20 patients (100%
delivery success). The EDD and delivery sheath accessed the aortic arch, deployed into the
aortic arch and were retrieved intact in 100.0% (21/21) of devices used. Coverage of all three
cerebral vessels was achieved in 95.0% (19/20) of cases prior to the TAVR procedure; in 1 case,
2 devices were attempted but the investigator was unable to successfully position the device as
intended due to poor visualization in an obese patient.

The EDD device performed as intended in 80.0% (16/20) of cases with complete cerebral vessel
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coverage from initial EDD positioning, passage of the TAVR delivery system, and positioning
and deployment of the TAVR device. The EDD remained in position with full coverage of all
cerebral vessels until after removal of the TAVR delivery system in 65.0% (13/20) of cases.
Device performance results are reported in Table 5.

The primary safety endpoint of in-hospital EDD and procedure related safety was not met by any
patient (0%) as there were no EDD adjudicated device or procedure related cardiovascular
deaths, major stroke disability, life-threatening (or disabling) bleeding, distal embolization,
major vascular/access site related complications or the need for acute cardiovascular surgery
reported (Table 6).

Secondary Endpoints
Procedure success was 80%, mean device deployment time was 16.413.8 minutes, and mean
total procedure time was 85.615.9 minutes. There was no obstruction to cerebral blood flow or
interference of the EDD with the valvuloplasty or TAVR procedure reported in any of the cases.

The composite (non-EDD related) in-hospital MACCE was 10% as a result of 2 major stroke
disabilities. One stroke occured the day following urgent surgical conversion after a failed
TAVR implant, and the second stroke occured in a patient whose procedure was complicated by
loss of ventricular capture from a temporary pacing lead in the setting of complete heart block,
requiring cardiopulmonary resuscitation. There was one major vascular complication (5.0%); a
thoracic aortic dissection occurring in the same patient who underwent 2 failed TAVR attempts
with urgent conversion to surgery. The dissection was diagnosed intra-operatively following
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manual manipulation of the TAVR device and removal. It was repaired surgically and the patient
recovered. There were 2 patients (10.0%) who experienced AKI (stage 1 (n=1), stage 3 (n=1))
related to contrast administration during the study procedure. There were a total of 4 non-EDD
related major bleeding events (20.0%), all of which resulted in a drop in hematocrit >15% and 5
minor vascular complications (25.0%), 3 of which (left groin hematoma, bilateral groin
hematomas, and bilateral femoral access site oozing) involved the EDD delivery system. All
bleeding complications resolved without sequelae.

At 30 days the hierarchical MACCE was 15%; in addition to the 2 in-hospital major stroke
disabilities, there was an additional non-cardiovascular death in a patient who developed
broncho-pneumonia that occurred after discharge but prior to 30-day follow-up. Primary and
secondary safety endpoints are summarized in Table 6.

DW-MRI
DW-MRI results are presented in Table 7. No patients were excluded due to unobtainable or uninterpretable DW-MRI images. New post-procedure DW-MRI lesions were found in 70%
(14/20) patients. This rate was not significantly different than the weighted mean of historical
control rates from studies reported in unprotected TAVR (70% vs. 76%)[9, 13, 15, 45, 53-55];
however, there was a 94% reduction in maximum single lesion volume (0.39 vs. 6.45 cm 3),[15,
45] a 65% reduction in mean single lesion volume (0.12 vs. 0.34 cm3),[13, 15, 45, 54, 55] a 57%
reduction in mean total lesion volume (0.7 vs. 1.64 cm3),[13, 15, 45, 54, 55] and a 94% reduction
in maximum total lesion volume (3.94 vs. 70.3 cm3).[15]
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Angiographic sub-study
100% of patient angiograms were suitable for complete analysis. 7 patients were classified as
aortic arch type I (35%), 9 type II (45%), and 4 type III (20%). Anatomical measurements,
presented as mean +/- standard deviation, are as follows: innominate artery RVD (11.49 +/1.54), take off angle from innominate artery and aortic arch (73.52 +/- 26.19), take off angle
from EDD after positioning (114.72 +/- 30.35), and take off angle from EDD after TAVR
(120.28 +/- 26.95). The only angiographic characteristic significantly associated with complete
device coverage before, during, and after the TAVR procedure was whether the device upper
stabilizer was anchored in the innominate artery at those respective time points (Prior: p = 0.01;
During: p = <0.0001; After: p = <0.0001). No baseline anatomical characteristics were
associated with the ability of the device to maintain coverage (Table 8).
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DISCUSSION
Peri-procedural stroke is a significant contributor to morbidity and mortality in high-risk patients
undergoing TAVR. Recent studies have demonstrated an early high-peaking hazard phase in the
period immediately following the procedure as well as an arterial distribution of periprocedural
cerebral infarcts reflective of typical embolic patterns[5, 56]. These data support embolization of
atherosclerotic debris during valve implantation and balloon aortic valvuloplasty as the most
likely mechanism for periprocedural stroke in TAVR, and provides the rationale for neuroprotection during the TAVR implant procedure. Neuro protection is not intended to completely
eliminate the risk of clinical stroke or neuro embolic events. Though approximately 50-65% of
all strokes occur during the procedure, an increased stroke risk is present in the months following
the procedure and is likely related to the high-risk profile of the patient population and
potentially thrombosis of the implanted valve.[57-59]

The DEFLECT study provides evidence for the feasibility, performance and preliminary efficacy
of the TriGardTM EDD. The EDD was placed in the aortic arch and successfully retrieved in all
cases, with proper positioning and protection of all cerebral vessels until completion of TAVR in
80% of cases. Thus, in the majority of cases the device was properly positioned to provide
neuroprotection during balloon valuvloplasty and valve prosthesis deployment, the period during
which the majority of cerebral embolic events have been demonstrated to occur[60, 61]. The
EDD was maintained in position until complete retrieval of the TAVR delivery system in 65% of
cases. Whether there is incremental benefit in retaining complete neuroprotection until complete
removal of the TAVR system remains to be seen. Several studies using TCD have shown that
the majority of microembolization occurs during balloon valvuloplasty and TAVR prosthesis
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positioning and deployment and not during the retrieval phase of the TAVR delivery system.[60,
61] TCD data gathered throughout the TAVR procedure during each DEFLECT case, will help
further clarify the precise period during which the EDD must be in place to provide optimal
protection.

It is important to note that most device performance failures (inability to position the EDD and
maintain its position) occurred in the first 1-2 cases at the investigational sites. As with any novel
device, a learning curve is expected and we did see placement improvement in later cases. We
predict further improvement in overall device performance with additional enrollment.

Though the proportion of patients with new ischemic lesions, and the maximum and average
number of new lesions were similar in DEFLECT-I as compared with historical controls,
maximum and mean single lesion volume were much smaller than the respective averages in the
reported literature. Overall, total lesion volume was smaller in DEFLECT-I, which was primarily
driven by the reduction in the single lesion volume. These results suggest that the TriguardTM
EDD device was successful in deflecting larger emboli away from the cerebral vessels, resulting
in significant reductions (up to 94%) in maximum single lesion volume. Similarly, mean lesion
volume was 65% lower compared to historical controls. While overall lesion numbers were
slightly higher compared to historical data, due to lower single lesion volume, maximum total
lesion volume on a per-patient basis was 18-fold smaller compared to the one study in the
reported literature, representing a 94% reduction in maximum total lesion volume.
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While 2 disabling strokes occurred, they occurred after TAVR and in association with urgent
surgical conversion of the failed TAVR procedure in the first case and following cardiac
resuscitation in the second case.

It is unlikely that these strokes reflect a failure of neuro-protection. Major stroke event rates
reported in similar trials range from 3.8%[62] to 5.0%[1] up to 30 days. We would not expect
complete elimination of neurologic events in our study; however, use of the Keystone Heart
TriGardTM should result in a decreased peri-procedural stroke rate associated with uncomplicated
TAVR as well as a reduction in silent ischemic events. While symptomatic strokes can result in
obvious disability, multiple studies have demonstrated the cognitive implications of DW-MRI
lesions in cardiac procedures.[16, 17, 41] Further, DW-MRI lesion volume may be a more
valuable measure than number of lesions because volume is most indicative of overall ischemic
burden and is predictive of clinical outcome after stroke.[46, 47] Following endovascular
procedures, mean lesion volume has been associated with vascular dementia and cognitive
changes.[48] Thus, the Keystone Heart EDD resulted in large relative reductions in single and
total lesion volumes compared with historical controls, suggesting that device utilization can
result decreased overall ischemic burden and post-operative cognitive changes. Neurocognitive
testing results will lend further support to this finding; however, a randomized trial comparing
protected vs. unprotected TAVR is necessary.

Performance of the TriGardTM EDD in this early series appears similar to other neuroprotection
devices. The Claret CE ProTM and the Embrella (Edwards Lifesciences, Irvine, CA, USA)
deflection system have been developed to lower the risk of cerebral embolism during the TAVR
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procedure. Results of first-in-human experiences with these devices have demonstrated
comparable technical success rates[38, 39]; however, the TriGardTM EDD may offer superior
protection against cerebral embolism due to its coverage of all three aortic arch vessels,
compared with the Claret CE ProTM and Embrella devices, which lack coverage of the left
subclavian artery.

Other complications including vascular and bleeding complications are commensurate with rates
seen in association with similar populations undergoing TAVR procedures, which range from
11.0%[62]- 16.2%[1] for vascular complications and from 9.3%[62] - 16.8%[1] for bleeding
complications and are not related to the TriGardTM. Acute kidney injury was reported in two
subjects 10.5% (2/19), one reported as Stage 3 and one reported as Stage 1. While an embolic
etiology cannot be excluded, these were likely related to contrast administration during the
TAVR procedure; in both cases, no contrast was administered during positioning of the EDD so
it is unlikely that use of the TriGardTM device contributed.

Lastly, the ability of the Keystone Heart EDD to maintain full 3-vessel coverage for the entire
TAVR procedure correlates with anchorage of its upper stabilizer in the innominate artery and
this angiographic marker can assist interventional cardiologists with device positioning. Proper
patient selection and upper stabilizer anchoring at procedure initiation can ensure cerebral
protection during TAVR.
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Study limitations
The DEFLECT study is a safety and feasibility study performed in a limited patient population
intended for CE Marking. The study is intended to continue enrollment to establish efficacy
compared to historic controls. These early results provide the proof of concept to proceed to a
larger prospective randomized clinical trial to establish the benefit of the EDD during the TAVR
procedure compared with TAVR alone.
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FIGURE REFERENCES AND LEGENDS

Figure 1. Diffusion weighted-magnetic resonance images: (A) Baseline. (B) Following embolic
event. Arrows indicate areas of restricted diffusion.

Figure 2. The Claret CE ProTM.

Figure 3. Embrella embolic deflector.

Figure 4. Keystone Heart TriguardTM Embolic Deflection Device.

Figure 5. Angiography demonstrating Keystone Heart TriguardTM device position. (A) Before
the TAVR procedure. White arrow indicates device upper stabilizer anchorage in innominate
artery. (B) During the TAVR procedure. (C) After the TAVR procedure. TAVR, transcatheter
aortic valve replacement.
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TABLES
Table 1. Key studies depicting the relationship between DW-MRI lesions and cognitive decline following cardiac procedures.
Study
Cardiac
Association
Number
Number of
Number of
Mean
Minimum/
Number
Procedure
with
of
patients
patients
lesion
Maximum
of lesions
cognitive
patients
developing
with
volume
lesion
per
decline
in study
new DWmultiple
volume
patient
MRI lesions
lesions
(range)
Restrepo CABG
Yes
13
4 (31%)
3
0.6 cm3
0.2 cm3/ 0.8
1 to 4
et al. [16]
cm3
Barber et Valvular
Yes
40
15 (41%)
7
<0.2 cm3 <0.2 cm3/ 3.0 1 to 17
al.[17]
replacement
cm3
surgery 
CABG
Lund et
Left heart
Yes
47
5 (15.2%)
2
Not
Not available 1 to 2
al.[18]
catheterization
available
Schwarz Coronary
Yes
84
8 (11.6%)
Not
0.237
0.013 cm3/
1 to 10
3
et al.[19] catheterization
available
cm
1.75 cm3
or CABG
Knipp et Valvular
No
30
14 (47%)
6
Not
0.05 cm3/ 1.9 1 to 7
al.[22]
replacement
available cm3
surgery
Gerriets
CABG
No
106
13 (15.1%)
Not
0.032
0.016 cm3/
Not available
et al.[23]
available
cm3*
0.15 cm3
Knipp et CABG
No
39
20 (51%)
10
Not
0.176 cm3/
1 to 7
3
al.[24]
available 0.922 cm
*Median lesion volume; mean not provided. CABG, coronary artery bypass grafting; DW-MRI, Diffusion Weighted-Magnetic
Resonance Imaging.
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Table 2. Common neurocognitive tests used.
Cognitive Domains

Tests

Attention

SYNDROM-KURZTEST*
TRAIL MAKING A*, †, ‡, §, | |
ZIMMERMAN JOINT/DIVIDED ATTENTION TEST§, | |
NUMBER/LETTER CANCELLATION*, #, * *
SYMBOL DIGIT MODALITIES TEST†
BELLS TEST#
WAIS-R DIGIT SYMBOL‡, §, | |, * *
LETTER-NUMBER SEQUENCING†

Executive Function

SYNDROM-KURZTEST INTERFERENCE LIST*, * *
STROOP COLOR-WORD INTERFERENCE*, ‡
TRAIL MAKING B*, †, ‡, | |, #

Language

NAMING, READING#
CONTROLLED ORAL ASSOCIATION‡
REGENSBURG WORD FLUENCY* *

Visual Memory

NONVERBAL LEARNING*, * *
SYNDROM-KURZTEST PICTORIAL MEMORY*, * *
REY-OSTERRIETH’S COMPLEX FIGURE TEST‡
TAYLOR’S COMPLEX FIGURE TEST‡
CORSI BLOCK-TAPPING TEST§, | |

Verbal Memory

VERBAL LEARNING MEMORY*, §, | |, * *
REY AUDITORY VERBAL LEARNING†, ‡

Psychomotor

LINE TRACING*
GROOVED PEGBOARD TEST†, ‡

Visual-constructive

WAIS BLOCK DESIGN*, ‡
HORN’S PERFORMANCE§, | |

WAIS, Wechsler Adult Intelligence Scale; WAIS-R, WAIS Revised
*Gerriets T, et al.[23]
†Barber P, et al.[17]
‡Lund C, et al.[18]
§Knipp SC, et al.[22]
| |Knipp SC, et al.[24]
#Restrepo L, et al.[16]
* *Schwarz N, et al.[19]
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Table 3. New embolic DW-MRI lesions after TAVR.
Study

N

Subjects with
Lesions

%

Weight

Contribution
to Proportion

Rodes-Cabau
60
41
0.68
0.34
0.24
2011[53]
Astarci 2011[54]
35
32
0.91
0.20
0.18
Kahlert 2010[13]
32
27
0.84
0.18
0.16
Ghanem 2010*[15]
22
16
0.73
0.13
0.09
Arnold 2010[9]
25
17
0.68
0.14
0.10
Total
174
0.76
* Total study size was N=30. N=22 subjects were imaged. DW-MRI, diffusion-weighted
magnetic resonance imaging; TAVR, transcatheter aortic valve replacement.
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Table 4. Baseline characteristics.

Age (years)

DEFLECT 1
(N = 20)
82.4 ± 6.5

Female

15 (75.0%)

Current smoker (within the last year)

1 (5.3%)

Ex- smoker

7 (36.8%)

Non-insulin Dependent Diabetes Mellitus

2 (10.0%)

Hypertension

15 (75.0%)

Hyperlipidemia

10 (50.0%)

Peripheral Vascular Disease

0 (0.0%)

Prior CVA

1 (5.0%)

Prior MI

3 (15.0%)

COPD

3 (15.0%)

Renal insufficiency

3 (15.0%)

History of left ventricular dysfunction

6 (37.5%)

History of angina pectoris

3 (15.0%)

Subject Characteristics

Current CCS functional classification at time of enrollment
Class I

18 (90.0%)

Class II

1 (5.0%)

Class III

1 (5.0%)

Class IV

0 (0.0%)

Left ventricular ejection fraction (%)

58.8 ± 15.0

Current NYHA class on enrollment admission
Class I

3 (15.0%)

Class II

4 (20.0%)

Class III

12 (60.0%)

Class IV

1 (5.0%)

History of prior CABG

3 (15.0%)

History of prior PCI

3 (15.0%)

History of prior aortic valvular surgery
1 (5.0%)
Values reported as mean ± SD or n(%). COPD, chronic obstructive pulmonary disease; CVA,
cerebrovascular accident; TIA, transient ischemic attack.
CABG, coronary artery bypass grafting; CCS, Canadian Cardiovascular Society; NYHA, New
York Heart Association; PCI, percutaneous coronary intervention.
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Table 5. Device performance.
Procedural Angiographic Analysis
N = 20

Prior to TAVR

EDD Access to Aortic Arch

During TAVR
Until After
Valve Implant
20 (100%)

After TAVR
removal

EDD is positioned in the aortic arch

20 (100%)

19 (95.0%)

15 (75.0%)

EDD covers all 3 vessels (innominate,
left common carotid, subclavian)

19 (95.0%)

16 (80.0%)

13 (65.0%)

EDD upper stabilizer is anchored in the
innominate artery ostium

17 (85.0%)

16 (80.0%)

12 (60.0%)

Able to retrieve the final EDD and
20 (100%)
remove the delivery system intact
Values reported as n (%). EDD, embolic deflection device; TAVR, transcatheter aortic valve
replacement.
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Table 6. In-hospital and 30 day clinical endpoints.
In Hospital
Clinical Endpoint Events
(N = 20)
Primary safety endpoint:
0 (0.0%)
composite in-hospital device and
procedure-related safety

Two sided
95% CI

30-Day

Two sided
95% CI

[0.0% 16.8%]

--

--

Secondary safety endpoints
Device-related safety (component)a
0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Cardiovascular mortality % (n/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Major stroke disability % (n/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Life-threatening (or disabling)
bleeding % (n/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Distal embolization (noncerebral)
from a vascular source requiring
surgery or resulting in amputation
or irreversible end organ damage
% (n/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Major vascular or access-related
complications % (n/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Need for acute cardiovascular
surgery % (n/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

15.0%
(3/20)

[1.2% 31.7%]

5.0% (1/20)

[0.1% 24.9%]

Primary Safety Composite

Procedure-related safety (hierarchical composite MACCE)
Composite MACCE
All cause mortality % (n/N)

10.0%
(2/20)
0.0% (0/20)

[1.2% 31.7%]
[0.0% 16.8%]

Major stroke disability % (n/N)

10.0%
(2/20)

[1.2% 31.7%]

10.0%
(2/20)

[1.2% 31.7%]

Life threatening (or disabling)
bleeding % (N/N)

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20)

[0.0% 16.8%]

Acute kidney injury- Stage 3
(including renal replacement
therapy) % (n/N)

5.0% (1/20) [0.0% - 24.9%] 5.0% (1/20)

[0.0% 24.9%]

Peri-procedural MI % (n/N)

0.0% (0/20) [0.0% - 16.8%] 0.0% (0/20)

[0.0% 16.8%]
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Major vascular complication %
(n/N)

5.0% (1/20) [0.0% - 24.9%] 5.0% (1/20)

Repeat procedure for valve
dysfunction % (n/N)

0.0% (0/20)

[0.0% 24.9%]

[0.0%-16.8%] 0.0% (0/20) [0.0%-16.8%]

Neurologic Events
10.0%
(2/20)

Stroke

[1.2% 31.7%]

10.0%
(2/20)

[1.2% 31.7%]

10.0%
(2/20)

[1.2% 31.7%]

Ischemic stroke

10.0%
(2/20)

[1.2% 31.7%]

Hemorrhagic stroke

0 .0% (0/20)

[0.0% 16.8%]

Major stroke disability

10.0%
(2/20)

[1.2% 31.7%]

Minor stroke disability

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20) [0.0%-16.8%]

5.0%†
(1/20)

[0.1% 24.9%}

5.0% (1/20)

Transient ischemic attack

0.0% (1/20)

[0.0% 16.8%]

0.0% (0/20) [0.0%-16.8%]

Encephalopathy

0.0% (0/20)

[0.0% 16.8%]

0.0% (0/20) [0.0%-16.8%]

20.0%
(4/20)

[5.7% 43.7%]

Intracranial hemorrhage

0 (0.0%)

[0.0% 16.8%]

0.0% (0/20) [0.0%-16.8%]

Life threatening or disabling bleeding

0 (0.0%)

[0.0% 16.8%]

0.0% (0/20) [0.0%-16.8%]

Minor bleeding

0 (0.0%)

[0.0% 16.8%]

0.0% (0/20) [0.0%-16.8%]

Major bleeding

20.0%
(4/20)

[5.7% 43.7%]

Cerebral infarction

0.0% (0/20) [0.0%-16.8%]
10.0%
(2/20)

[1.2% 31.7%]

[0.1% 24.9%}

Bleeding Complications
Major bleeding

20.0%
(4/20)

20.0%
(4/20)

[5.7% 43.7%]

[5.7% 43.7%]

[0.0% 0.0% (0/20) [0.0%-16.8%]
16.8%]
Values reported as n (%). CI, confidence interval; MACCE, major adverse cardiac and
cerebrovascular events; MI, myocardial infarction.
*There were a total of 2 clinical strokes. Both strokes were classified as major stroke disability.
†1 stroke demonstrated an abnormality on neuro-imaging and was also classified as cerebral
infarction.
Intracranial hemorrhage

0 (0.0%)
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Table 7. Individual subject diffusion-weighted magnetic resonance imaging data.
DW-MRI measure
DEFLECT-I
Historical
Percent reduction
(n=20)
weighted average
(DEFLECT-I vs.
historical weighted
average)
Proportion of patients
70%
76%[9, 13, 15, 45,
-6%
with new ischemic
53-55]
lesions
Maximum number of
28
20[15, 45, 53]
-new lesions
Mean number of new
4.4[13, 15, 40, 45,
-16%
5.17.04
53-55]
lesions  SD
Maximum single lesion
0.39
6.45[15, 45]
-94%
3
volume (cm )
Mean single lesion
0.34[13, 15, 45,
-65%
0.120.13
3
54, 55]
volume  SD (cm )
Maximum total lesion
3.94
70.3[15]
-94%
volume (cm3)
Mean total lesion
1.64[13, 15, 45,
-57%
0.700.98
54, 55]
volume  SD (cm3)
*Average single lesion volume was calculated for each patient by dividing total lesion volume by
the lesion number in each individual patient. DW-MRI, diffusion-weighted magnetic resonance
imaging; SD, standard deviation.
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Table 8. Basline demographic and procedural characteristics and successful device coverage.
Variable
Overall
EDD maintained coverage
P-value
after TAVR
Yes
No
Age
82.4 ± 6.55
81.92 ± 7.02
83.29 ± 5.99
0.67
Gender (female)
15 (75%)
10 (77%)
5 (71%)
0.79
History of smoking
8 (42%)*
6 (46.2%)
2 (33.3%)
0.60
History of diabetes
2 (10%)
1 (7.7%)
1 (14.3%)
0.22
History of hypertension
15 (75%)
9 (69.2%)
6 (85.7%)
0.42
History of hyperlipidemia 10 (50%)
8 (61.5%)
2 (28.6%)
0.16
History of PAD/CAD
0 (0%)
0 (0%)
0 (0%)
N/A
Prior MI
3 (15%)
2 (15.4%)
1 (14.3%)
0.95
History of LV
6 (37.5%)*
4 (40%)
2 (33.3%)
0.79
Dysfunction
History of angina
3 (15%)
2 (15.4%)
1 (14.3%)
0.95
LVEF (%)
0.67
58.8  15
56.91  15.39
63.00  14.83
NYHA Class
I
3 (15%)
1 (7.7%)
2 (28.6%)
0.45
II
4 (20%)
4 (30.8%)
0 (0%)
III
12 (60%)
7 (53.9%)
5 (71.4%)
IV
1 (5%)
1 (7.7%)
0 (0%)
Prior CABG
3 (15%)
2 (15.4%)
1 (14.3%)
0.95
Prior PCI
3 (15%)
3 (23.1%)
0 (0%)
0.17
Prior aortic valve surgery 1 (5%)
0 (0%)
1 (14.3%)
0.14
Aortic arch
Type I 7 (35%)
5 (38.4%)
2 (28.6%)
0.70
classification
Type
9 (45%)
5 (38.4%)
4 (57.1%)
II
Type
4 (20%)
2 (15.4%)
2 (28.6%)
III
Innominate artery RVD
0.58
11.49  1.54
11.35  1.63
11.76  1.43
EDD upper stabilizer
12 (60%)
12 (92.3%)
0 (0%)
P < 0.0001
maintained anchorage in
innominate artery
EDD lower stabilizer in
17 (89.5%)*
12 (92.3%)
5 (83.3%)
0.55
position
TAVR
Medtronic 10 (50%)
6 (46.2%)
4 (57.1%)
0.64
device
Edwards
10 (50%)
7 (53.8%)
3 (42.9%)
implanted
Ostial stenosis innominate 1 (5%)
1 (7.7%)
0 (0%)
1.00
artery
Take off angle from
73.5 ± 26.2
71.23 ± 29.28
77.56 ± 20.61
0.61
innominate artery and
aortic arch
Take off angle from EDD 114.7 ± 30.4*
112.5 ± 33.83
119.5 ± 95.42
0.65
after positioning
Take off angle from EDD 120.3 ± 27.0*
120.3 ± 27.0
N/A
N/A
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after TAVR
Calcification ascending
aorta
Degree of
Mild
calcification
in ascending Moderate
aorta
Severe

7 (35%)

4 (30.8%)

3 (42.9%)

0.80

4 (20%)

2 (15.4%)

2 (28.6%)

0.35

3 (15%)

2 (15.4%)

1 (14.3%)

0 (0%)

0 (0%)

0 (0%)

Calcification in aortic
15 (75%)
10 (76.9%)
5 (71.4%)
1.0
arch
Location of Proximal
8 (40%)
6 (46.2%)
2 (28.6%)
0.89
calcification
Mid
7 (35%)
4 (30.8%)
3 (42.9%)
in aortic
arch
Distal
0 (0%)
0 (0%)
0 (0%)
segment
Degree of
Mild
4 (20%)
2 (15.4%)
2 (28.6%)
0.24
calcification Moderate
10 (50%)
7 (53.9%)
3 (42.9%)
in aortic
Severe
1 (5%)
1 (7.7%)
0 (0%)
arch
*indicates missing values. CABG, coronary artery bypass grafting; CAD, coronary artery
disease; EDD, embolic deflection device; LV, left ventricular; LVEF, left ventricular ejection
fraction; MI, myocardial infarction; NYHA, New York Heart Association; PAD, peripheral
artery disease; PCI, percutaneous coronary intervention; RVD, reference vessel diameter;
TAVR, transcatheter aortic valve replacement.

